Get the Stockscreener App
0.8208
8.40%
-0.0753
After Hours:
.91
0.0892
+10.87%
Sutro Biopharma Inc stock is traded at $0.8208, with a volume of 1.67M.
It is down -8.40% in the last 24 hours and down -56.11% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
See More
Previous Close:
$0.8961
Open:
$0.8854
24h Volume:
1.67M
Relative Volume:
1.27
Market Cap:
$68.76M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.4611
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-38.75%
1M Performance:
-56.11%
6M Performance:
-79.06%
1Y Performance:
-76.88%
1-Day Range:
$0.8208
$0.965
1-Week Range:
$0.7621
$1.3667
52-Week Range:
$0.7621
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.8208 | 68.76M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal
Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal
Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance
Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks
Bay Area biotech company once worth $2B guts staff, departing execs get $600K - SFGATE
Cattle Post Gains on Friday, Helped by Cash Strength - The Globe and Mail
Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada
Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India
Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals
Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India
Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK
Sutro prioritizes preclinical ADC programs - BioWorld Online
Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com
New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter
This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView
Sutro puts lead ADC on hold, cuts staff and changes CEO - pharmaphorum
Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8 - Marketscreener.com
Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating -March 14, 2025 at 06:39 am EDT - Marketscreener.com
Director buying at Canadian National Railway (CNR) - The Globe and Mail
Sutro Biopharma Names New CEO; Plans to Reduce Workforce by Nearly 50% After Portfolio Review - Marketscreener.com
Fierce Biotech Layoff Tracker 2025: Sutro halves staff; GRObio restructures - Fierce Biotech
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Sutro Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Sutro Biopharma stock down on portfolio review (STRO:NASDAQ) - Seeking Alpha
Sutro Biopharma Announces Strategic Review and Leadership Change - TipRanks
SUTRO BIOPHARMA, INC. SEC 10-K Report - TradingView
Sutro Biopharma shifts focus to ADC pipeline, appoints new CEO By Investing.com - Investing.com Canada
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
99,027 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
135,675 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '25 |
Option Exercise |
0.00 |
9,125 |
0 |
94,025 |
| NEWELL WILLIAM J | CEO |
Mar 04 '25 |
Option Exercise |
0.00 |
31,125 |
0 |
291,625 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '25 |
Option Exercise |
0.00 |
7,875 |
0 |
100,642 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 01 '25 |
Option Exercise |
0.00 |
25,125 |
0 |
131,868 |
| Chung Jane | PRESIDENT AND COO |
Mar 01 '25 |
Option Exercise |
0.00 |
31,875 |
0 |
102,217 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 01 '25 |
Option Exercise |
0.00 |
20,275 |
0 |
93,227 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '25 |
Option Exercise |
0.00 |
11,250 |
0 |
35,370 |
| NEWELL WILLIAM J | CEO |
Mar 01 '25 |
Option Exercise |
0.00 |
65,500 |
0 |
285,703 |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):